Introduction
Asthma is a chronic inflammatory disorder of the airways, which is characterized by excessive sensitivity of the lung to various stimuli. Asthma affects millions of people worldwide with many clinical phenotypes in both adults and children. 1 The prevalence of asthma continues to increase, with more than 300 million people around the world suffering from this disease.2 Although asthma cannot be cured, it can almost always be controlled, but the methods of assessing control remain unsatisfactory. Symptoms and lung function tests are used routinely to monitor asthma but are limited respectively by either subjectivity or by only presenting an instantaneous view of airway function.
An objective method to monitor airway inflammation and the effect of therapy is required therefore in the management of paediatric asthma. Several approaches have been proposed to assess airway inflammation including exhaled nitric oxide (eNO) measurement. Currently, symptom scores and lung function have been used as a guide to adjust anti-inflammatory treatment in controlling asthma.3'4 Measurement of lung function by using spirometry or daily peak flow recording combined with symptoms may provide strong evidence of measurement of asthma control.5 Other objective tools to monitor airway inflammation including induced sputum and eosinophils in broncho-alveolar lavage (BAL) fluid are not easily applied in clinical practice, especially in young children. On the other hand, a number of studies have demonstrated that airway inflammation may be present in asthmatic patients whose lung function is normal and clinically well controlled.6'7 Nitric oxide (NO) has been identified as a signalling molecule in the inflammatory process of the airways; thus exhaled nitric oxide has been proposed as a noninvasive, quick and easy method to assess airway inflammation. 8 Currently, inhaled glucocorticosteroids (GCS) are recommended to both control asthma symptoms, and improve lung function by reducing airway inflammation.3'9 Levels of eNO in asthmatic children are increased compared with normal subjects. Higher levels of eNO are seen during an asthma exacerbation and the level is decreased when therapy with either inhaled or systemic glucocorticosteroids is commenced. [10] [11] [12] This suggests that eNO may be used as a tool to monitor airway inflammation and in the assessment of asthma control.
Eosinophils and eosinophil cationic protein (ECP) in blood and sputum have been applied to the clinical practice of asthma to determine the efficacy of inhaled GCS. 13 Since eNO is correlated with eosinophils in induced sputum and with bronchial hyper-responsiveness, this may be a more accessible method of measuring eosinophil inflammation. 14 Thus, using eNO as a measurement of control in asthma management, compared with conventional methods such as spirometry, peak flow readings, bronchial challenge and sputum induction needs to be evaluated.
This review aims to evaluate the relationship between exhaled nitric oxide and other markers of airway inflammation including symptom scores, spirometry, bronchial challenge, bronchial biopsies and sputum induction. The review also considers whether measurement of eNO is a way to improve the management of asthma and a tool to monitor airway inflammation in asthmatic children.
Chemical and biological features of nitric oxide
Nitric oxide is composed of nitrogen and oxygen. It is a small (30 Da) uncharged molecule with an unpaired electron, the latter making it radical.15 It is a colourless and odourless gas and is soluble both in water (up to 2 mmol/L at 20°C and one atmosphere) and lipid, therefore freely diffusible in the environment of the cell. 16 In the body, NO has a short half-life (0.1-0.5 s) and being a highly reactive molecule it is rapidly converted to nitrogen dioxide, nitrite and nitrate.17
Cellular origins of NO
Nitric oxide production takes place in many cells and tissues. It can regulate many body fimctions including: blood pressure, respiration, blood clotting, bacterial killing, cancer prevention, brain and sexual function. 18 In mammals, nitric oxide is synthesized from the amino acid L-arginine, by enzymes called NO synthases (NOS) to form NO and citrulline ( Figure  1 ). 16, 19 Nitric oxide synthases were first identified in 1990 by Bredt and Snyder, and exist in three forms.20 Two are constitutive, neuronal NOS (nNOS or Type I) and endothelial NOS (eNOS or Type III) while one is inducible NOS (iNOS or Type II).16119-23 nNOS and eNOS are constitutively expressed, dependent upon calcium for activity, and are responsible for the release of small amounts ofNO within seconds or minutes after receptor stimulation with agonist. In contrast, iNOS is capable of much greater levels of activity, is independent of calcium concentrations, and can be expressed by a wide range ofcells after it has been induced by inflammatory cytokines, endotoxin, and, in airways, some environmental pollutants and allergens. The release of NO by iNOS takes several hours and continues for days after exposure to the activating stimulus. The induction of iNOS is blocked by 
ONOO-
NO2-S-GSNO peroxynitrite nitrite S-nitrosothiols Figure 1 Diagram indicating NO synthesis from L-arginine. The amino acid L-arginine is converted to NO by the NO synthases, cNOS and iNOS. cNOS is calcium dependent. The acitivity ofNOS is inhibited by the L-arginine analogues, L-NAME, and L-NMMA. iNOS activity is stimulated by the action of cytokines (TNF-a, IFN-y, IL-1f3) on the other hand this acitivity is decreased by TGFA glucocorticoids and aminoguanidine. NO is finally converted to peroxynitrite, nitrate and S-nitrosothiols.
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Exhaled nitric oxide in paediatric asthma Ratnawati and PS Thomas 165 glucocorticosteroids and some cytokines such as transforming growth factor-fl, but these have little or no effect on both nNOS and eNOS activity. 23, 24 Inducible NOS generates more NO than constitutive NOS and can continue to do so for prolonged periods. 25 In the human lung, NOS has been localized to a variety of cells including epithelium, endothelium, neurones, eosinophils, neutrophils, macrophages, mast cells, platelets, fibroblasts and smooth muscle cells. 26 The iNOS is the predominant form in airway epithelium. Calcium and calmodulin-dependent NOS can be induced by stimulation of cultured human epithelial cell lines with lipopolysaccharide or proinflammatory cytokines (TNF-a, IFN-y, IL-1,8). [27] [28] [29] In human lung the predominant sites of nNOS are confined to nonneuronal cells such as the capillary endothelial cells of the alveolar septa, which suggests that NO may play a role as an endothelium-derived regulator of capillary permeability, a modulator of cholinergic neural transmission or an inhibitor of platelet aggregation.30 NO appears to have a generally beneficial role when produced in low concentrations by cNOS, but it may result in increased inflammatory responses and tissue damage when produced in large amounts by iNOS.29 '3 Pulmonary physiology of nitric oxide The synthesis of NO by cNOS appears to be responsible for the regulation of various respiratory physiological processes. In the human lung, the predominant sites of nNOS are nonneuronal, that is, capillary endothelial cells of the alveolar septa, which suggests that NO may play a role as an endotheliumderived regulator of capillary permeability, a modulator of cholinergic neural transmission, or an inhibitor of platelet aggregation.30
Role as a vasodilator (vascular effects)
Nitric oxide modulates pulmonary and systemic vascular tone through its vasodilator properties. 32 Agonists such as bradykinin, acetylcholine, histamine and sheer stress may activate cNOS, resulting in the release of picomolar concentrations of NO within seconds.1 33 In vascular endothelium, these agonists result in an influx of intracellular calcium with consequent stimulation of cNOS. Nitric oxide formed from L-arginine by this enzyme diffuses to nearby smooth muscle cells, in which it stimulates soluble guanylate cyclase (sGC), resulting in enhanced synthesis of cyclic GMP from guanosine triphosphate (GTP). The reaction of nitric oxide with ferrous iron in the haem prosthetic group of the soluble guanylate cyclase in vascular smooth muscle cells increases the concentration of cyclic GMP, leading to vascular relaxation.34 Moreover, NO-stimulated cGMP formation relaxes not only arteries but also veins. 35 However, the relaxation mechanism in smooth muscle via increased cGMP is unknown. Many possibilities have been suggested, including the inhibition of inositol triphosphate, inhibition of a cAMP phosphodiesterase, dephosphorylation of the light chain of myosin, activation of protein kinases, stimulation of membrane Ca2+ ATPase, opening of K+ channels, increased sequestration of cytosolic Ca2+, and inhibition of Ca2+ influx.31
Role as a nonadrenergic noncholinergic (NANC) transmitter In the peripheral nervous system, NO may function as a neurotransmitter of the nonadrenergic noncholinergic nervous system. 36 It is released from nerves them selves, since cNOS is activated by calcium entry when the nerve is depolarized. 31 Nitric oxide is released together with acetylcholine from cholinergic nerves and modulates cholinergic and adrenergic neural responses, resulting in altered airway and vascular tone. 22 Nonadrenergic noncholinergic transmitters change blood flow, they potentially alter the output of NO and endothelins from the vascular endothelium, and these mediators may in turn influence airway smooth muscle tone. 37 The NANC relaxant nerves are the predominant bronchodilating influence on the airway smooth muscle tone in humans and in many mammalian species and NANC relaxation of the airways is mediated by postganglionic parasympathetic nerves. Nitric oxide is one of several potential transmitters that mediate noncholinergic parasympathetic responses. It has also been identified as a neurotransmitter of inhibitory nonadrenergic noncholinergic (i-NANC) nerves in airways of several species.38-40 Furthermore, i-NANC stimulation of human airways results in an increase in cyclic GMP without any increase in cyclic AMP. The density of nNOS-immunoreactive nerves is greatest in proximal airways and diminishes peripherally, which is consistent with a reduction in i-NANC response in more peripheral airways.41
Nitric oxide and breathing
Complexes ofNO bound to thiols (sulphydryl, Figure 2 ), called S-nitrosothiols (SNOs), are able to affect control of the breathing by the brain. S-nitrosothiol is of importance in the regulation of breathing, because it induces increased minute ventilation in response to hypoxia via deoxyhaemoglobin-derived S-nitrosothiol. When NO is released from SNO it activates the enzyme guanylyl cyclase to generate cGMP. This is thought to cause increased viscosity ofthe mucus from bronchial epithelial cells and to relax bronchial smooth muscle.
This induces the ventilatory effects of hypoxia at the level ofnucleus tractus solitarius.42 In human bronchial smooth muscle SNO effects relaxation.43 One study shows an association of decreased SNO concentrations with acute asthma in children, suggesting that there is a deficiency of an endogenous bronchodilator in the human asthmatic airway lining fluid.44
The role of NO in the lung Nitric oxide has both protective and deleterious effects in the human lung. It causes airway smooth muscle relaxation,45 is a potent vasodilator in the pulmonary circulation4' and has a crucial role in matching ventilation to perfusion in the lungs.42 It may also be involved in bronchial mucus clearance by increasing ciliary clearance, thus protecting the lung against pathogens.46
Endogenous NO can increase plasma exudation by elevating the blood flow in postcapillary venules, resulting in airway oedema,47 whereas NOS inhibitors may also increase plasma exudation, suggesting that the basal release of NO exerts inhibitory effects on the microvascular leakage.48 In rat airways, the Chronic Respiratory Disease NOS-inhibitor L-NAME increases basal leakage. However, after iNOS induction by endotoxin, L-NAME inhibits plasma leakage. Therefore these seemingly contradictory effects may be explained by differing levels of NO and different sites of production. 49 Nitric oxide has been suggested to be able to modulate both acute and chronic inflammatory reactions.505' It regulates the functional activity of many immune and inflammatory cell types including macrophages, T lymphocytes, antigen-presenting cells, mast cells, neutrophils and eosinophils.52
Secretion efffects
There are controversial reports on the role of NO in the modulation of mucus secretion. The NO inhibitor, L-NAME, has been reported to increase basal airway mucus secretion in the ferret trachea, suggesting that NO generated by the constitutive NOS enzyme inhibits mucus secretion.53 Nitric oxide donors were, however, demonstrated to increase mucus secretion in human airways in vitro.54 The role of iNOS was also investigated in cultured guinea pig airway cells after exposure to inflammatory stimuli. The resulting mucus hypersecretion was effectively inhibited by L-NMMA, 167 indicating that iNOS-derived NO stimulates mucus 22 secretion. Endogenous NO may be an important mediator of mucociliary clearance as NOS inhibition leads to a decreased ciliary beat frequency in bovine airway epithelial cells.46
Airway smooth muscle
The airway parasympathetic nerves are a source of NO in the lung. Nonadrenergic noncholinergic (NANC) relaxation of the airways is mediated by postganglionic parasympathetic nerves. NANC parasympathetic relaxant nerves are the primary relaxant nerves innervating airway smooth muscle (ASM) in most mammalian species, including humans. 38, 55 These nerves can reverse a near maximal contraction of isolated tracheal or bronchial smooth muscle preparations in vitro or can completely dilate markedly constricted airways in vivo. 56 In contrast to the human airways, where the major neurotransmitter of the inhibitory NANC pathway is NO, in the guinea pig, vasoactive intestinal peptide (VIP) is believed to play a prominent role next to NO in the inhibitory NANC response.22 '38 Experimental hyper-responsiveness in the guinea pig induced by respiratory virus infection is thought to be mediated by inhibition of the NOS enzymes and hence NO-induced smooth muscle relaxation. 55 The role of NO in pathogenesis of asthma Although understanding the link between NO and airway inflammation remains incomplete, increasing evidence supports the contention that eNO may be considered a readout of certain aspects of airway inflammation, particularly in atopic asthma.24 Nitric oxide has a selective suppressive effect on the THI subset of helper T cells. It leads to the assumption that raised levels of NO may interfere with the balance between TH1 and TH2 cell types, leading to a predominantly TH2 type response associated with allergic asthmatic symptoms. 57 One study using bronchial hyper-responsiveness to AMP to diagnose asthma confirms that eNO is a useful tool to differentiate between asthmatic and nonasthmatic subjects.58
Nitric oxide could play a role as an inflammatory mediator in the mechanism of airway inflammation. Nitric oxide production by iNOS in response to TNF-a, IL-ll3, and INF-y has been widely studied in several different species and many different pulmonary cells, including vascular smooth muscle cells, bronchial smooth muscle cells, and airway epithelial cells.28'59 It is thought that increased levels of NO in airway epithelial cells and alveolar macrophages diffuses to the airway lumen, elevating the NO in expired breath.
Macrophages
Nitric oxide has been identified in mammalian physiology as a mediator of macrophage activation.60 Human alveolar macrophages are able to express iNOS and support a role for this enzyme in pulmonary inflammatory pathophysiology.61 Alveolar macrophages may synthesize NO after exposure to various cytokines and endotoxins.41 During the inflammatory reaction in the airway, iNOS is induced in macrophages by pro-inflammatory cytokines and produces abnormally high amounts of NO.62 Besides being an NO producer, the macrophage is also a target for NO, since some data suggest that NO inhibits inflammatory cytokine production by human alveolar macrophages.63
Mast cells
In the inflammatory process, mast cells are the first cells to respond to allergen in IgE-mediated inflammation. The cytoplasm of mast cells is packed with dense granules that act as high-concentration storage sites for histamine, heparin, cytokines and proteases.15 Nitric oxide can act as an inhibitor of histamine release from rat peritoneal mast cells. Rat serosal mast cells have been reported to synthesize NO from L-arginine, but whether NO is produced by activated human lung mast cells is not yet certain.66
Eosinophils
In asthma, eosinophils have a pathogenic role after activation and degranulation. Eosinophils accumulate at the site of allergic inflammation and release lipid mediators, cationic proteins and cytokines, which enhance inflammation.67 Nitric oxide produced during inflammation binds to haeme, and can increase eosinophil survival via nitrosyl-haeme, while in contrast, free NO induces eosinophil apoptosis in vitro.68 
Detection of NO in exhaled breath
Involvement of NO in airway inflammation and the presence ofNO in exhaled breath ofhumans means that NO may be used as a marker to assess asthmatic patients beside other conventional methods currently used. Furthermore, the biological products of NO (for example, nitrosothiols, nitrite, nitrate and peroxynitrite) can also be detected in airway by breath condensate.70 There is clearly a need for NO to be compared with other markers of asthma, particularly in young children in whom symptoms and lung function may not be reliable.
Technique of measuring exhaled NO According to guidelines from the European Respiratory Society and the American Thoracic Society (ATS) there are two acceptable procedures to measure exhaled NO in adults and children that involve either online or offline measurements. Online measurement refers to eNO estimation by direct expiration into the analyser with a real-time display of eNO breath profiles, whereas offline testing refers to collection of exhalate into a suitable inert reservoir for later analysis.71 73 The fractional eNO concentration (FENO) in online measurement is expressed in parts per billion (ppb), which is approximately equivalent to nanolitres per litre (nL/L). Exhaled is denoted by E, and inspired by i, in identification of the test results such as FENO and FINO, where F denotes 'fractional'. Nitric oxide output is the amount of eNO per unit time, and is denoted by VNO. It is calculated from the product ofNO concentration in nanolitres per litre and expiratory flow rate in litres per minute, corrected for BTPS. Meanwhile, offline NO collection of exhaled NO refers to the fractional NO concentration in exhalate from a vital capacity collection with the flow rate in litres per second.71
The advantage of eNO is that the measurement is completely noninvasive and can therefore be performed repeatedly. It can also be performed in children with severe airflow obstruction where invasive or difficult techniques are not possible. eNO may offer a means to detect and monitor asthma in the general population, as well as to monitor the efficacy of specific treatment in individual patients. It may be useful for monitoring whether treatment is adequate, because eNO is reduced by anti-inflammatory treatments.21
Nitric oxide in clinical practice Elevated levels of eNO have been associated with several lung diseases and can be used to monitor inflammation. It may be a diagnostic tool as well as Chronic Respiratory Disease having a role in monitoring asthma control. Increased levels of eNO have been associated with acute exacerbations of asthma under suboptimal control. Increased therapy with GCS will reduce airway NO levels. 74 The measurement of NO may have a wide range of applications as a longitudinal marker for the effect of treatment in inflammatory and infectious diseases. During symptomatic upper respiratory tract infection in otherwise healthy subjects, NO levels were more than threefold higher than levels measured 3 weeks post infection.75 In bronchiectasis, where proinflammatory cytokines are present in high levels in bronchial secretions, eNO levels were threefold higher compared with healthy controls.76 Levels ofNO are also increased in exhaled breath in disorders such as systemic lupus erythematosus and liver cirrhosis in addition to other diseases of children.77-79 The levels of eNO are reported to be lower than normal in smokers and caffeine drinkers and can be normal or decreased in some disorders, such as chronic cough, primary pulmonary hypertension and cystic fibrosis. [80] [81] [82] [83] Factors affecting measurement of eNO in normal subjects Levels of eNO in normal subjects are influenced by several factors; it will be significantly increased as a result of breath holding.84 Measurement of eNO with a noseclip may result in higher values due to increased diffusion of NO from the nasopharynx into the upper respiratory tract. It is recommended that measurement eNO be conducted without a noseclip, to avoid contamination of eNO by nasal NO since the velopharyngeal aperture is closed by this manoeuvre. Consuming L-arginine results in an increased eNO in normal subjects, most likely reflecting increased synthesis due to provision of more substrate for NOS.85 To reduce the effects of nitrate-containing food, a mouthwash may be performed prior to eNO measurement.86 In addition, the production of eNO increases during exercise and hyperventilation, although the mechanism is not yet certain.21 In the clinical setting, standardized procedures need to be applied, including technique, equipment, environmental and individual factors, particularly if comparisons are to be made between studies.79 eNO in normal children Measurement of eNO in children may assist in the diagnosis and management of asthmatic patients as several studies have shown that the levels of eNO Exhaled nitric oxide in paediatic asthma Ratnawati and PS Thomas 169 in healthy children are significantly lower than in asthmatic children.87-92 A study by Artlich et al. found that healthy control subjects have significantly lower levels of eNO than asthmatic subjects who had had recent symptoms despite inhaled glucocorticosteroid treatment, but these levels were not significantly different from asthmatics who had no symptoms. 89 Another study has shown that there was no difference in the level of eNO between normal children and asthmatic children on regular inhaled GCS. The level of eNO, however, was significantly higher in subjects using bronchodilator therapy only. 93 It is thought that the elevated levels of eNO in asthmatics who have not taken GCS is due to induction of iNOS as a result of inflammation.57 eNO in atopic children
The level of eNO in asthmatic children is positively associated with the degree of atopy. In atopic asthmatic children the levels of eNO are higher than those of nonatopic asthmatic children.91 A study by Ludviksdottir et al. showed that subjects with atopic asthma had higher concentrations of eNO compared with those who had nonatopic asthma, and this group had eNO levels that were similar to nonatopic nonasthmatic subjects. 94 In mildly atopic asthmatic patients, the levels of eNO were two to three times those seen in normal subjects. 95 The level of eNO is higher in children who have more reactions to allergens on skin prick testing.87 '96 Exhaled NO in asthmatic children Current measures of the efficacy of treatment rely on symptoms and lung finction monitoring. The use of a sensitive NO analyser is likely to be a useful noninvasive method to monitor airway inflammation, especially in young children in whom other objective diagnostic tools, such as spirometry or induced sputum, cannot be easily applied in clinical practice.
Procedures usedfor assessment of asthmatic children
There are several methods available for identifying the presence of airway inflammation in asthmatic children, which can be either noninvasive or invasive. In clinical practice, symptom scores and spirometry are the standard guide to the level of severity, and indicate the adjustments required in anti-inflammatory treatment for asthma control.3'4 Bronchoscopy with bronchoalveolar lavage (BAL) and bronchial biopsies is an invasive method but remains a gold standard for assessing airway inflammation.97'98 Bronchial challenge testing can be used to investigate the presence of airway hyperresponsivenes (AHR) and the degree of inflammation.
The peripheral blood eosinophil count may be used for detecting ongoing allergic inflammation ofthe airway. 62 Recently, sputum induction has been proposed as a relatively non-invasive, simple and safe method for evaluation of airway inflammation.99 Newer methods are emerging to monitor airway inflammation by measuring the level of eNO in the breath. eNO may serve as a suitable direct indicator of airway inflammation in asthma and perhaps other respiratory diseases.950
Exhaled NO measurement in childhood asthma The relationship between eNO and childhood asthma has been reported in several studies.79'91'96'101"02 eNO levels are significantly higher in asthmatic children who have not been treated with inhaled GCS58 and studies in adults would suggest that it is derived predominantly from the lower respiratory tract.'03
In asthma, the level of exhaled NO has been shown to correlate with both airway hyper-reactivity and also with the percentage of eosinophils in induced sputum in both adults'14"04 and children. 105"106 Research has reported that eNO correlates closely with eosinophils in BAL fluid in asthmatic children.107
Analysis of induced sputum is a valid method for assessing airway inflammation in asthma. Induced sputum analysis can be used to investigate inflammatory cells and their mediators, such as eosinophils and eosinophil cationic protein, as well as mast cells in asthmatic children.' 1 1 A study by Little et al. showed that sputum eosinophil counts are increased in asthmatics and fall after inhaled GCS treatment.112 It has been suggested that an increase in sputum eosinophils is a potentially useful marker in predicting loss of asthma control.'13 Obtaining adequate samples for sputum, however, can be difficult, particularly in children under 6 years.'08" '14 In a study of patients with difficult asthmatic and persistent symptoms that continued despite two weeks oral GCS therapy, eNO had a significant correlation with eosinophil inflammation from endobronchial biopsies. This study found that eNO can be used as a way to identify a group with GCS insensitive inflammation and a group with normal levels of eNO.' 1' In those with difficult asthma, eNO can be used to monitor the anti-inflammatory response to glucocorticosteroids. A study found there is a group of asthmatic subjects in which eNO decreases following treatment with oral prednisolone and this group demonstrated an improvement in peak expiratory flow and PC20. Two additional subgroups were also www.CRDjournal.com Exhaled nitric oxide in paediatric asthma Ratnawati and PS Thomas 170 identified, one with eNO levels persistently raised even after prednisolone and one with normal eNO levels both before and after prednisolone.116 A longitudinal study by Roberts et al. suggests that the eNO level can predict future exacerbations in asthmatic children following exposure to environmental grass pollens. The level of eNO correlated with allergen exposure and eNO increased with a decline in asthma control. Lung function, however, did not reflect either allergen exposure or asthma severity.117
A study of asthmatic adults by Green et al. demonstrated that adjustment in asthma medication using induced sputum eosinophil counts can reduce asthma exacerbations and hospital admissions compared with traditional assessments such as symptoms, peak expiratory flow and use of ,B2 adrenergic agonists. When sputum could not be produced by the patient, eNO was used as a surrogate marker of eosinophilic airway inflammation. '18 Exhaled NO may reflect the amount of cytokineinduced inflammation in the airways. Corroborative evidence for this view has been shown by increased eNO levels after allergen challenge but not after histamine challenge in adult asthmatic subjects.119 eNO levels have a significant correlation with other markers of asthmatic inflammation such as bronchial challenge, serum IgE, total eosinophil count and serum eosinophil cationic protein.120 During an acute asthma exacerbation eNO is a more sensitive indicator of asthma disease activity than serum markers of inflammation such as eosinophil cationic protein (ECP) or soluble interleukin 2 receptor.'21 Furthermore, a study by Nelson et al. shows that the level of eNO in asthmatic children is still higher than normal, even after airway obstruction resolved with GCS treatment, in other words, that inflammation may persist after obstruction has resolved.101 Nonetheless, inhaled GCS are capable of reducing the level of eNO in asthmatic children allergic to house dust mite.122
The study by Little et al. 112 showed that eosinophils and eNO predicted improvement in FEV1 after oral prednisolone during 2 weeks of therapy with a sensitivity of 76% and specificity of 75%, which would be better than our current practice. These data suggest that eNO may be a more sensitive measure of childhood asthma than spirometry.101
Recently, several studies have shown that distal airway inflammation is a prominent feature in asthma. 123, 124 A mathematical model, based on different exhalation flow rates, confirms that NO is produced by both bronchial and alveolar sources. 125'126 A clinical study by Lehtimaki et al. 127 found that asthmatic patients with nocturnal symptoms have higher eNO concentration than those with only Chronic Respiratory Disease daytime symptoms, suggesting eNO can be used to assess distal airway inflammation.
Management of asthma
Several guidelines recommend anti-inflammatory medication, preferably with inhaled GCS, as first-line treatment to gain control of the disease as fast as possible. In children and adults, early and effective therapy with inhaled GCS results in long-term remission in the majority of patients.128 '129 In view of the known disadvantages of using GCS in children, it is important therefore to use the minimum dose required. Thus a combination therapy of a GCS with other therapies such as long-acting (32 adrenergic agonists,130 theophylline,131 and leukotriene antagonists132 have been implemented and have shown advantages over inhaled GCS alone in term of a significant reduction in mild and severe exacerbations and improvement in lung function.
The use ofanti-inflammatory drugs such as GCS have been associated with a decrease in eNO in asthmatic patients, both in adults and children.'0'74'133-135 eNO is elevated in breath of those asthmatic subjects who are not taking inhaled or oral GCS. It decreases to the level seen in normal subjects when treatment with inhaled GCS is commenced. One study has shown that patients who inhale GCS regularly had a significantly lower eNO compared with patients who only had bronchodilators, and this level was not different when compared to normal children. 93 eNO may be useful as a repeatable measurement of inflammation in order to optimize anti-inflammatory therapy.79 Measurement of eNO has been shown to predict worsening asthma control when inhaled GCS are withdrawn in adults.'36 Another study in asthmatic adults has shown that when the dose of GCS was reduced, there was an increased level of eNO compared with baseline, but no significant deterioration in spirometry or change in peak flow variability.137 This suggests that eNO could also be a useful and sensitive guide to asthma inflammatory activity and treatment efficacy in children. 0'21"38 eNO may prove also to be a more sensitive measure of childhood asthma than spirometry and an important addition to the assessment of asthma severity in the paediatric population.'0' eNO might be used as an inflammatory marker in asthma and predict a response to inhaled corticosteroids in individual patients.120 On the basis of these findings, measurement of eNO has been suggested as a sensitive marker to monitor airway inflammation, and may indicate the efficacy of antiinflammatory treatment to control the asthmatic patient,93 suggesting that eNO measurements may be used for long-term management of asthma.
It is a prevalent view that GCS should be used in long-term therapy to control persistent asthma. Longterm use of inhaled GCS, however, causes side effects such as oropharyngeal candidiasis and hoarseness. It also produces systemic side effects such as skin bruising and thinning, suppression of bone growth, decreased bone mineralization, delayed sexual development, and the development of cataracts.139'140 Exacerbations of asthma often occur when the treatment is discontinued. In this setting, eNO may help titrate the dose of GCS to obtain the optimum and lowest possible amount required to successfully manage asthma, with a minimum of side effects from GCS therapy. Further studies, however, are in progress to study this hypothesis.
Conclusion
Asthma is a chronic inflammatory disorder of the airways, which involves genetic and environmental factors in the progression ofthe disease. Nitric oxide is a free radical gas produced by a variety of cells in the human lung, which has been proved to have an important role in pathogenesis of asthmatic airway inflammation. The presence of NO in exhaled breath of human and increased eNO levels in the breath of asthmatic children compared with normal children suggests that eNO may be used as a convenient method to monitor airway inflammation. It has been shown that eNO is an indicator of inflammation as it correlates well with other inflammatory markers such as eosinophils in induced sputum and eosinophils in airway biopsies or BAL. The advantage ofeNO is that it is easy to perform and the results are available immediately, unlike other measures of inflammation. eNO will need to be studied in longitudinal clinical trials, and compared with standard symptom scores, spirometry, PEF and other measures ofairway inflammation to prove its usefulness.
It has also been found, however, in asthmatics who are insensitive to GCS, that eNO has no correlation with clinical responses. Further studies on eNO in paediatric practice are required, particularly with regard to using this information in the long-term control of asthma, measuring the degree of inflammation, and monitoring compliance.
